Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference39 articles.
1. Systemic therapy for estrogen receptor–positive, HER2-negative breast cancer;Burstein;N Engl J Med,2020
2. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study;Harbeck;Ann Oncol,2021
3. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system;Hudis;J Clin Oncol,2007
4. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020
5. Patients' quality of life and side-effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer;Tolaney;Breast,2021
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ki-67 Testing in Breast Cancer: Assessing Variability With Scoring Methods and Specimen Types and the Potential Subsequent Impact on Therapy Eligibility;Applied Immunohistochemistry & Molecular Morphology;2024-03
2. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma;Cancer Biology & Medicine;2024-01-03
3. An Automated Breast Volume Scanner-Based Intra- and Peritumoral Radiomics Nomogram for the Preoperative Prediction of Expression of Ki-67 in Breast Malignancy;Academic Radiology;2024-01
4. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-12
5. Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer;The Breast;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3